Directory of Peptide API Manufacturing Plants

Wuhan Newtop Biotech Co., Ltd., located in Wuhan, Hubei, is a pharmaceutical manufacturing enterprise integrating R&D, production, sales and service, focusing on organic chemistry and pharmaceutical chemistry, with its own R&D center and laboratory. The company mainly focuses on polypeptides and pharmaceutical raw materials, including Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, GHK-Cu, Melanotan, Thymosin alpha-1, LL-37, Selank, Epitalon, etc., and provides peptide freeze-dried powder and raw materials. With peptide synthesis, purification and active ingredient separation capabilities, the production system has obtained GMP, ISO 9001, HSE and other quality certifications, and has a D-level (ISO 8)/C-level (ISO 7) clean workshop; products are mainly exported to Europe, the United Kingdom, the United States, Canada, Australia and other countries and regions.

High-volume foreign trade foundries with stable purity ≥ 98%

Chongqing Zhixia Chemical Co., Ltd. (related to Nanjing Chenruisheng Biomedical Technology) was established in September 2023. It is a small and micro enterprise, mainly engaged in the research and development and supply of polypeptide GLP-1 raw materials, representing products including Semaglutide, Tirzepatide and other polypeptide raw materials. The business model is factory, customization and service, and the products are mostly marked as "for scientific research or export only". The company announced a registered capital of 500,000 yuan, 10–50 employees, and an annual turnover of about 3-5 million yuan. The contact information is shared with Nanjing Chen Ruisheng (the same phone/email address), and is positioned as a peptide small molecule GLP-1 raw material supplier for the global scientific research and export market.

Conscientia Industrial is a core member of the Conscientia Group, headquartered in China, focusing on the R&D, manufacturing and global marketing of high-quality APIs (APIs), peptides, nutritional ingredients, cosmetic ingredients and fine chemicals. Its manufacturing facilities and products comply with international standards such as GMP and ISO, and its APIs strictly comply with USP, BP, EP, JP, KP, CP and other pharmacopoeial requirements. In the field of peptides, the company provides high-purity peptide synthesis and supply. The products cover hundreds of peptides such as α-Casozepine, AOD-9604, BPC-157, CJC-1295, GHK-Cu, GLP-1 (smectin, tilapopeptide, liraglutide, mazdopeptide, retalutide, etc.), beauty and scientific research peptides, all of which have been verified by HPLC with purity of 98% +. The supply is stable and supports rapid global shipments. It is positioned to provide peptides and raw materials for the global life science and chemical industries.

Zhejiang Peptide Biotechnology Co., Ltd. (a national-level specialized and new key "small giant" enterprise) focuses on the research and development, production and application of polypeptides. It has a national post-doctoral scientific research station, Shaoxing academician expert workstation and provincial enterprise research institute. It is the first polypeptide synthesis engineering research center in Zhejiang Province. It has obtained 108 relevant invention patents and is one of the domestic leaders in the large-scale production of polypeptides. The company builds a "one main two-wing, two-wheel drive" strategy: mainly pharmaceutical polypeptides and technical services, and cosmetic polypeptides and other polypeptides are two wings. The product line includes more than 60 kinds of peptide APIs, covering obesity, diabetes, gastrointestinal diseases and other fields. Many core products have been filed/approved in many countries; more than 40 kinds of cosmetic peptide raw materials cover anti-wrinkle, anti-aging, repair, whitening and so on. The production system has passed FDA certification in the United States and has been certified by halal, EcoVadis, ISO and other management systems. With large-scale production capacity: the annual output of polypeptide powder is 8000kg, and the annual output of polypeptide bulk solution is 2000t. Products are exported to the United States, the European Union, Canada, South Korea, Japan, Russia, etc., and establish stable cooperation with internationally renowned companies.

Shenzhen Peptide Chuangsheng Technology Co., Ltd. is a pioneer supplier of high-quality active peptides (cosmetic peptides) based in Shenzhen and radiating the world. It focuses on molecular biology and AI-driven peptide structure-activity research to provide efficient, verifiable and sustainable active peptide raw material solutions for scientific research institutions, pharmaceutical groups, medical cosmetic institutions and functional skin care brands. It has a Peptide AI design system and a peptide professional-grade laboratory, with a raw material purity of 99.8% pharmaceutical grade, adopts a biological + chemical synthesis green process (zero solvent instead of DMF), and a transdermal rate of > 80%, which meets the EU ECOCERT, US FDA gras, Japan JHOSPA and other regulations; and provides customized peptide synthesis (minimum order of 100g, 3–6 weeks delivery). The product covers 100 cosmetic peptides with 9 major efficacy matrices (blue copper peptide GHK-Cu, acetylhexapeptide-8/aquirelin, palmitoyl pentapeptide-4, conopeptide, etc.), 100% made in China, and serves 100 + customers worldwide (European pharmaceutical giant, North American pure beauty brand, CJK head beauty group).

Sichuan Ampelbo Biotechnology Co., Ltd. (Chengdu Boke Pharmaceutical Technology Co., Ltd., Chengdu) is a professional R&D, production and sales of amino acid derivatives (amino alcohols, amino aldehydes, N-methyl amino acids, amino acid tert-butyl esters, Boc/Fmoc/Cbz protected amino acids, benzyl esters, amino acid amides, etc.). It also provides polypeptides, piperidine derivatives and chiral amine series products. It can provide domestic and foreign customers with high-quality pharmaceutical intermediates and fine chemicals from grams, kilograms to tons. Its products are exported to Europe and North America. It is a small high-tech/trade-oriented enterprise (with a staff size of about 8–50 people). The polypeptide is one of its product lines, with a partial amino acid protecting group and a polypeptide side chain/intermediate direction.

Shenzhen Han Yu Pharmaceutical Co., Ltd. (listed on the Shenzhen Stock Exchange, 300199, listed in 2011) is a national high-tech enterprise specializing in the R&D, production and sales of polypeptide drugs and small nucleic acids. Founded in 1998, it is an early listed polypeptide drug enterprise in China. The company has built a national and local joint engineering laboratory for polypeptide drugs, a national public experimental center for innovative polypeptide drugs, and a national pilot technology platform for the preparation of polypeptide drugs. It has undertaken a number of national-level projects and won the second prize of the National Technology Invention Award. It has passed the GMP/cGMP certification in China, the United States, the European Union, Brazil, Australia, South Korea and other countries, and has four major production bases: Shenzhen Pingshan Preparation Base, Wuhan Peptide Featured API Base (through the China/United States/Australia GMP certification, which is being expanded), Gansu Chengji Pharmaceutical Intermediates Base, Yunnan Dali Industrial Hemp Base, etc., to open up the whole chain control from raw materials to drugs. The APIs are sold to 20 + countries and regions, and the preparations are sold to 90 + countries and regions. The polypeptide products include GLP-1 injections such as liraglutide, smeclutide, tirpotide, etc., atoxiban, etibapeptide, etc., and have CRDMO (custom R&D + custom production) capabilities. The monomer reactor capacity is 100L-10000L.

Shanghai QYAOBIO Co., Ltd. (ChinaPeptides/QYAOBIO), founded in October 2008, is a technology-based enterprise focusing on peptide synthesis, protein expression, and antibody preparation. In China, peptide solid phase synthesis (SPPs) technology was adopted earlier. The company maturely mastered 300 + peptide special modification core technologies, and has branches and scientific research laboratories in Suzhou, Wuhan, and Ezhou; cumulatively serving more than 50,000 customers worldwide, covering more than 50 countries and China's Hong Kong, Macao, and Taiwan regions, of which more than 90% are biomedical research institutions and pharmaceutical companies such as universities, hospitals, laboratories, and research institutes. Has passed ISO 9001: 2015 quality system certification, > 99% peptide synthesis success rate, provide HPLC/MS report and optional endotoxin/salt type test, as soon as 3 days delivery; core business is peptide synthesis, protein expression and antibody preparation.

Focus on overseas Biohacking channels, mature composite peptide kits

Active spot merchants on B2B platforms, sending overseas directly in small batches

Hefei HeSheng Biotechnology Co., Ltd. was established in 2014 and is located in Hefei High-tech Zone. It is an innovative polypeptide biotechnology company with polypeptide technology as its core. It focuses on the customization, research and development, production and service of polypeptide-related products, and is committed to becoming an international polypeptide CRDMO integrating polypeptide scientific research and customization, drug polypeptide intermediates and impurity customization, peptide API production, drug polypeptide research and development and process development, and beauty polypeptide research and development and production. The factory area of the company is about 4,000 square meters, and there are polypeptide R&D and production workshops such as synthesis, purification and analysis, with a total planned annual raw material production capacity of 200 kg (powder). It has more than 100 patents (including 24 invention patents). The service covers research custom polypeptide synthesis (long peptide, difficult peptide, branch peptide), labeling (isotope, fluorescence), cyclic peptide (amide ring, disulfide ring, subscription peptide ring, thioether ring), modification (glycopeptide, phosphorylation, peg, etc.), deuterated service, and polypeptide drug impurity customization; GMP small test/pilot and amplification production (mg to kg grade) can be carried out.

Founded in 2013 in Hefei, Cellmano Biotech Limited is a high-tech company focused on the research and industrialization of solid phase peptide synthesis methods. The company has been engaged in the R&D and manufacturing of solid-phase polypeptide synthesis since 2011. It has a R&D center that meets the requirements of solid-phase synthesis, lyophilization and purification, and a complete set of analytical and testing instruments. The synthesis records, purification methods and test reports of each batch of products are archived in detail. Its main business includes peptide intermediates, cosmetic peptides (cosmetic peptides), custom synthesis of peptides, and peptide CMO services. It can provide customized peptides from mg to kg, from crude to 98% purity, and establish more than 2,000 commonly used catalog peptides in stock (gradually improve inventory, deliver in as fast as one week) to serve customers around the world. Approximately 10–50 employees.

Founded in 2014, Hangzhou Go Top Peptide Co., Ltd. (Go Top Peptide) is a national high-tech enterprise focusing on the R&D and production of polypeptides and related derivatives. It is the governing unit of the polypeptide branch of the China Biochemical Pharmaceutical Industry Association. The company has more than 4,000 square meters of polypeptide research and development center in Hangzhou, and has established two commercial polypeptide production bases in Shangyu and Anji, Zhejiang. It has a number of polypeptide production lines, large-scale polypeptide synthesis equipment, imported HPLC analysis and preparation equipment, and is equipped with a GMP standard clean laboratory. It has passed ISO9001: 2015 quality management system certification. Provides peptide customization, modification, catalogue peptides and scientific/pharmaceutical peptide products.

Harbin Jixianglong Biotechnology Co., Ltd. was established at the end of 2011 and is located in the Harbin Limin Development Zone. It covers an area of 23,000 square meters, 16,000 square meters of buildings, a registered capital of 18.31 million yuan, a net asset of 110 million yuan, and 260 employees (70 R&D). It is a national high-tech enterprise, Heilongjiang Specialized New SME and Synthetic Peptide Drug Technology Innovation Center. The company focuses on independent R&D and custom R&D and production of peptide drugs, forming a two-wheel drive pattern of peptide raw material sales and formulation R&D services (CRO). It has built a GMP-certified peptide raw material production workshop, equipped with more than 300 sets of equipment such as solid phase synthesizers, preparation liquid chromatography, lyophilizers, and HPLC. The company has a complete industrial chain of R&D, approval and production, and has obtained 10 API production approvals (the third in the country in terms of quantity) using its own technology; Smeglutide and Tirpotide have completed US DMF filings with the US FDA and obtained NDCs for sale in US pharmacies; it has 16 invention patents (including 5 compound patents).

Sinopep-Allsino Biopharmaceutical is a global supplier of commercial grade APIs and a full range of polypeptide/oligonucleotide CDMOs. Providing end-to-end CMC development and cGMP production from early R&D to commercialization for new drugs (NCE) and innovative pharmaceutical companies since 2009. The company's current production capacity of polypeptides is about 20–30 tons/year. It has built a large-scale GMP oligonucleotide (ASO, siRNA and GalNAc, AOC, liposome and other conjugates) production facility that can produce thousands of kilograms per year in Lianyungang, Jiangsu Province. At the same time, it has small molecule generic drugs and NCE commercial production capacity. The quality and regulatory system is mature. It has passed four FDA on-site inspections, strictly follows FDA and ich guidelines, and provides process development, analytical method development and verification, stability research, and global IND/NDA declaration support.